Henk P. Roest

Dr. Henk P. Roest

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2022 in Biomaterials
Verified
Journal Article
Open access
JWJorke Willemse
Jorke Willemse
GTGilles van Tienderen
Gilles van Tienderen
EHElena Victoria Anthoinette van Hengel
Elena Victoria Anthoinette van Hengel
ISIvo Schurink
Ivo Schurink
DVDiana van der Ven
Diana van der Ven
MVMonique Verstegen
Monique Verstegen
Human cholangiocyte organoids are promising for regenerative medicine applications, such as repair of damaged bile ducts. However, organoids are typically cultured in mouse tumor-derived basement membrane extracts (BME), which is poorly defined, highly variable and limits the direct clinical applications of organoids in patients. Extracellular matrix (ECM)-derived hydrogels prepared from decellularized human or porcine livers are attractive alternative culture substrates. Here, the culture and expansion of human cholangiocyte organoids in liver ECM(LECM)-derived hydrogels is described. These hydrogels support proliferation of cholangiocyte organoids and maintain the cholangiocyte-like phenotype. The use of LECM hydrogels does not significantly alter the expression of selected genes or proteins, such as the cholangiocyte marker cytokeratin-7, and no species-specific effect is found between human or porcine LECM hydrogels. Proliferation rates of organoids cultured in LECM hydrogels are lower, but the differentiation capacity of the cholangiocyte organoids towards hepatocyte-like cells is not altered by the presence of tissue-specific ECM components. Moreover, human LECM extracts support the expansion of ICO in a dynamic culture set up without the need for laborious static culture of organoids in hydrogel domes. Liver ECM hydrogels can successfully replace tumor-derived BME and can potentially unlock the full clinical potential of human cholangiocyte organoids.

14 December 2019 in Cells
Verified
Journal Article
Open access
PDF file
João LoboJoão Lobo
João Lobo
AGAd J.M. Gillis
Ad J.M. Gillis
ABAnnette van Den Berg
Annette van Den Berg
LDLambert C.J. Dorssers
Lambert C.J. Dorssers
GBGazanfer Belge
Gazanfer Belge
LLLeendert H. J. Looijenga
Leendert H. J. Looijenga
Liquid biopsy-based biomarkers, such as microRNAs, represent valuable tools for patient management, but often do not make it to integration in the clinic. We aim to explore issues impeding this transition, in the setting of germ cell tumors, for which novel biomarkers are needed. We describe a model for identifying and validating clinically relevant microRNAs for germ cell tumor patients, using both in vitro, in vivo (mouse model) and patient-derived data. Initial wide screening of candidate microRNAs is performed, followed by targeted profiling of potentially relevant biomarkers. We demonstrate the relevance of appropriate (negative) controls, experimental conditions (proliferation), and issues related to sample origin (serum, plasma, cerebral spinal fluid) and pre-analytical variables (hemolysis, contaminants, temperature), all of which could interfere with liquid biopsy-based studies and their conclusions. Finally, we show the value of our identification model in a specific scenario, contradicting the presumed role of miR-375 as marker of teratoma histology in liquid biopsy setting. Our findings indicate other putative microRNAs (miR-885-5p, miR-448 and miR-197-3p) fulfilling this clinical need. The identification model is informative to identify the best candidate microRNAs to pursue in a clinical setting.

26 January 2020 in Clinical Transplantation
Verified
Journal Article
Open access
PDF file
AMAlix P. M. Matton
Alix P. M. Matton
JSJasmijn W. Selten
Jasmijn W. Selten
HRHenk P. Roest
Henk P. Roest
JJJeroen de Jonge
Jeroen de Jonge
JIJan N. M. Ijzermans
Jan N. M. Ijzermans
Luc J.W. van der LaanLuc J.W. van der Laan
Luc J.W. van der Laan
Background: Cell‐free microRNAs (miRs) have emerged as early and sensitive biomarkers for tissue injury and function. This study aimed to investigate whether the release of hepatocyte‐derived microRNAs (HDmiRs) and cholangiocyte‐derived miRs (CDmiRs) correlates with hepato‐cholangiocellular injury and function during oxygenated, normothermic machine perfusion (NMP) of human liver grafts.Methods: Donor livers (n = 12), declined for transplantation, were subjected to oxygenated NMP (6 hours) after a period of static cold storage (median 544 minutes (IQR 421‐674)). Perfusate and bile samples were analyzed by qRT‐PCR for HDmiR‐122 and CDmiR‐222. Spearman correlations were performed between miR levels and currently available indicators and classic markers.Results: Both HDmiR‐122 and CDmiR‐222 levels in perfusate at 30 minutes of NMP strongly correlated with hepatocyte injury (peak perfusate AST) and cholangiocyte injury (peak biliary LDH). In bile, only CDmiR‐222 correlated with these injury markers. For hepato‐cholangiocellular function, both miRs in perfusate correlated with total bilirubin, while HDmiR‐122 (in perfusate) and CDmiR‐222 (in bile) correlated with bicarbonate secretion. Both the relative ratio of HDmiR‐122/CDmiR‐222 and AST in perfusate at 30 minutes significantly correlated with cumulative bile production, but only the relative ratio was predictive of histopathological injury after 6 hours NMP.Conclusion: Early levels of HDmiR‐122 and CDmiR‐222, in perfusate and/or bile, are predictive of excretory functions and hepato‐cholangiocellular injury after 6 hours NMP. These miRs may represent new biomarkers for graft viability and function during machine perfusion.

6 August 2021 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
HRHenk P. Roest
Henk P. Roest
JIJan N. M. Ijzermans
Jan N. M. Ijzermans
Luc J.W. van der LaanLuc J.W. van der Laan
Luc J.W. van der Laan
Background: Extracellular microRNAs (miRNAs), released from cells into biofluids, have emerged as promising biomarkers for diagnostic and prognostic purposes. Several RNA isolation methods are available for the analysis of these cell-free miRNAs by RT-qPCR. Not all methods, however, are equally suitable for different biofluids. Here, we extracted total RNA from four very diverse biofluids: serum, urine, bile, and graft preservation fluid (perfusate). Four different protocols were used: a phenol-chloroform extraction and alcohol precipitation in combination with a precipitation carrier (QP) and three different column-based isolation methods, one with phenol-chloroform extraction (RN) and two without (NG and CU). For this range of clinical biofluid samples, we evaluated the potential of these different RNA isolation methods assessing recovery efficiency and the co-purification of RT-qPCR inhibiting compounds. Results: Differences were observed between each of the RNA isolation methods in the recovery of cel-miR-39, a synthetic miRNA spiked in during the workup procedure, and for endogenous miRNAs. Co-purification of heparin, a known RT-qPCR inhibitor, was assessed using heparinase I during cDNA synthesis. RT-qPCR detection of synthetic miRNAs cel-miR-39, spiked in during RNA workup, cel-miR-54, spiked in during cDNA synthesis, and endogenous miRNAs was strongly improved in the presence of heparinase I for some, but not all, isolation methods. Other, co-isolated RT-qPCR inhibitors were not identified, except for biliverdin, which co-isolated from some bile samples with one of the methods. In addition, we observed that serum and urine contain compounds that enhance the binding of heparin to certain solid-phase columns. Conclusions: For reliable measurements of miRNA-based biomarkers in biofluids, optimization of RNA isolation procedures is recommended as methods can differ in miRNA detection and in co-purification of RT-qPCR inhibitory compounds. Heparinase I treatment confirmed that heparin appeared to be the major RT-qPCR inhibiting compound, but also biliverdin, co-isolated from bile, could interfere with detection.

1 May 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
MBMarcel J.C. Bijvelds
Marcel J.C. Bijvelds
FRFloris J.M. Roos
Floris J.M. Roos
KMKelly F. Meijsen
Kelly F. Meijsen
HRHenk P. Roest
Henk P. Roest
Monique M. A. VerstegenMonique M. A. Verstegen
Monique M. A. Verstegen
HJHugo R. de Jonge
Hugo R. de Jonge
In cystic fibrosis (CF), loss of CF transmembrane conductance regulator (CFTR)-dependent bicarbonate secretion precipitates the accumulation of viscous mucus in the lumen of respiratory and gastrointestinal epithelial tissues. We investigated whether the combination of elexacaftor (ELX), ivacaftor (IVA) and tezacaftor (TEZ), apart from its well-documented effect on chloride transport, also restores Phe508del-CFTR-mediated bicarbonate transport. Epithelial monolayers were cultured from intestinal and biliary (cholangiocyte) organoids of homozygous Phe508del-CFTR patients and controls. Transcriptome sequencing was performed, and bicarbonate and chloride transport were assessed in the presence or absence of ELX/IVA/TEZ, using the intestinal current measurement technique. ELX/IVA/TEZ markedly enhanced bicarbonate and chloride transport across intestinal epithelium. In biliary epithelium, it failed to enhance CFTR-mediated bicarbonate transport but effectively rescued CFTR-mediated chloride transport, known to be requisite for bicarbonate secretion through the chloride-bicarbonate exchanger AE2 (SLC4A2), which was highly expressed by cholangiocytes. Biliary but not intestinal epithelial cells expressed an alternative anion channel, anoctamin-1/TMEM16A (ANO1), and secreted bicarbonate and chloride upon purinergic receptor stimulation. ELX/IVA/TEZ has the potential to restore both chloride and bicarbonate secretion across CF intestinal and biliary epithelia and may counter luminal hyper-acidification in these tissues.

10 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAndrew I. Morrison
Andrew I. Morrison
JKJesse E. Kuipers
Jesse E. Kuipers
HRHenk P. Roest
Henk P. Roest
Luc J.W. van der LaanLuc J.W. van der Laan
Luc J.W. van der Laan
CWCharlotte M. de Winde
Charlotte M. de Winde
RMReina E. Mebius
Reina E. Mebius
Lymphoid organ function depends on fibroblastic reticular cells (FRCs), the non-hematopoietic mesenchymal stromal cells that crucially support immune activity in human lymph nodes (LNs). The in vitro study of human immunology requires physiological LN models, yet the inclusion of FRCs in current models is lacking. Here, we created an organotypic LN hydrogel model, containing native immune cells from LN tissue and ex vivo cultured autologous FRCs. During a oneweek culture period, enrichment of FRCs into the LN model benefited the viability of all immune cell populations, particularly B cells, and promoted the presence of certain subsets including CD4+ naïve T cells and unswitched (US) memory B cells. FRCs enhanced the production of immune-related cytokines and chemokines, such as B cell activating factor from the TNF family (BAFF), CXC motif chemokine ligand 12 (CXCL12), CC motif chemokine ligand 19 (CCL19) and interleukin-6 (IL-6). Functionality of the LN model was assessed through T cell activation by CD3 stimulation or initiation of an allogenic reaction with different maturation statuses of monocyte-derived dendritic cells (moDCs). Interestingly, T cell expansion was restricted in FRC-enriched LN models, reflecting an intrinsic characteristic of LN FRCs. As such, this organotypic LN model highlights the influence of FRCs on immune cells and allows an opportunity to further study antigen-induced immune responses, e.g. vaccine or immunotherapy testing.